- Euro Rate Expected to Be Slashed by Half a Point
- Bank of England Could Keep Cutting to 0%
- Private Sector Cuts Jobs; Planned Layoffs Jump
- Marsh & McLennan Posts Third-Quarter Net Loss
- Euro Unlikely to Fight Back Against Dollar
- Pound Seen Staying Near Current Lows vs Dollar
- Bond Insurers Ambac and MBIA Post Wide Losses
- ArcelorMittal Earnings Disappoint, Cuts Output
- Election Is No Reason to Buy Stocks: Analysts
- Go Bananas on Fruit Companies: Strategist
- It's All Over But the T-Shirts
- And So It Goes ...
- Valliere: Can Obama Permanently Jump-start Confidence?
- At McCain Headquarters -- Johnny Cash!
- Time to Move to the Lawn
- Obama Appears and ... Nothing
- Lightning Round: Cisco, Morgan Stanley, Bristol-Myers and More
- Cramer's Outrage: The U.S. Treasury
- Quanta 4Q outlook lower than Wall Street's
- Quanta 3Q profit rises 11 percent
- Transocean 3Q profit rises 13.7 percent
- Cerberus head: Country can't let automakers fail
- Corinthian Colleges reaffirms fiscal 2009 outlook
- Henry Schein 3Q profit rises, but gives dour view
- Maidenform Brands lowers 2008 outlook
- Irish unemployment hits 10-year high
- Economy tops concerns as Obama cruises in Vt.
- Cox Radio 3Q profit slips on declining revenue
Text Size 
PITTSBURGH - Drugmaker Mylan Inc. said it has received approval to market a generic version of UCB's epilepsy drug Keppra, and has started shipping the drug.
Mylan, based in Canonsburg, Pa., said the Food and Drug Administration approved its application to market generic versions of the drug, also called Levetiracetam, in 250 milligram, 500 mg and 750 mg tablets. It said U.S. sales of Keppra totaled about $1 billion in the 12 months ended Sept. 30.
The U.S. patent on the drug will expire in January 2009. UCB, a Belgian biopharmaceuticals company, will maintain the exclusive right to market Keppra for pediatric use until that time.
Mylan shares fell 9 cents to $9 in after-hours trading, after rising 32 cents, or 3.7 percent, to close at $9.09 during the day session.
Print
Email
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes